These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30509296)

  • 1. Autoimmune disorders but not heparin are associated with cell-free fetal DNA test failure.
    Dabi Y; Guterman S; Jani JC; Letourneau A; Demain A; Kleinfinger P; Lohmann L; Costa JM; Benachi A
    J Transl Med; 2018 Dec; 16(1):335. PubMed ID: 30509296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting.
    Miltoft CB; Rode L; Ekelund CK; Sundberg K; Kjaergaard S; Zingenberg H; Tabor A
    Ultrasound Obstet Gynecol; 2018 Apr; 51(4):470-479. PubMed ID: 28640470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-free fetal DNA analysis in maternal plasma as screening test for trisomies 21, 18 and 13 in twin pregnancy.
    Le Conte G; Letourneau A; Jani J; Kleinfinger P; Lohmann L; Costa JM; Benachi A
    Ultrasound Obstet Gynecol; 2018 Sep; 52(3):318-324. PubMed ID: 28833712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective first-trimester screening for trisomies by cell-free DNA testing of maternal blood in twin pregnancy.
    Sarno L; Revello R; Hanson E; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Jun; 47(6):705-11. PubMed ID: 26970114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation use is associated with lower fetal fraction and more indeterminate results.
    Shree R; MacKinnon HJ; Hannan J; Kolarova TR; Reichel J; Lockwood CM
    Am J Obstet Gynecol; 2024 Jan; 230(1):95.e1-95.e10. PubMed ID: 37429430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between fetal fraction on cell-free DNA testing and first-trimester markers for pre-eclampsia.
    Rolnik DL; da Silva Costa F; Lee TJ; Schmid M; McLennan AC
    Ultrasound Obstet Gynecol; 2018 Dec; 52(6):722-727. PubMed ID: 29318732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of maternal autoimmune disease on cell-free DNA test characteristics.
    MacKinnon HJ; Kolarova TR; Katz R; Hedge JM; Vinopal E; Lockwood CM; Shree R; Delaney S
    Am J Obstet Gynecol MFM; 2021 Nov; 3(6):100466. PubMed ID: 34418590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for trisomies by cell-free DNA testing of maternal blood: consequences of a failed result.
    Revello R; Sarno L; Ispas A; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Jun; 47(6):698-704. PubMed ID: 26743020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could high levels of cell-free DNA in maternal blood be associated with maternal health and perinatal outcomes?
    Konuralp Atakul B; Koc A; Adiyaman D; Kuyucu M; Sahingoz Yildirim AG; Saka Guvenc M; Erdogan KM; Sengul B; Oztekin DC
    J Obstet Gynaecol; 2020 Aug; 40(6):797-802. PubMed ID: 31769709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Routine first-trimester screening for fetal trisomies in twin pregnancy: cell-free DNA test contingent on results from combined test.
    Galeva S; Konstantinidou L; Gil MM; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2019 Feb; 53(2):208-213. PubMed ID: 30353581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cell-free fetal DNA analysis in maternal plasma as a screening test for trisomy 21 in twin pregnancies].
    Le Conte G; Letourneau A; Jani J; Kleinfinger P; Lohmann L; Costa JM; Benachi A
    Gynecol Obstet Fertil Senol; 2018; 46(7-8):580-586. PubMed ID: 29929941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What would be missed in the first trimester if nuchal translucency measurement is replaced by cell free DNA foetal aneuploidy screening?
    Huang LY; Pan M; Han J; Zhen L; Yang X; Li DZ
    J Obstet Gynaecol; 2018 May; 38(4):498-501. PubMed ID: 29433355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of screening for aneuploidies by cell-free DNA analysis of maternal blood in twin pregnancies.
    Bevilacqua E; Gil MM; Nicolaides KH; Ordoñez E; Cirigliano V; Dierickx H; Willems PJ; Jani JC
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):61-6. PubMed ID: 25297464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for Common Fetal Trisomies in Twin Pregnancies: First-Trimester Combined, Cell-Free DNA, or Both?
    Pasquini L; Ponziani I; Periti E; Marchi L; Luchi C; Accurti V; D'Ambrosi F; Persico N
    Fetal Diagn Ther; 2019; 46(4):217-222. PubMed ID: 30466098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cell-free fetal DNA on invasive prenatal diagnostic tests in a real-world public setting.
    Herraiz I; Villalba A; Ajuria E; Barasoain A; Mendoza A; Pizarro N; Escribano D; Galindo A
    J Perinat Med; 2019 Jul; 47(5):547-552. PubMed ID: 30849049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Not all low fetal fraction cell-free DNA screening failures are at increased risk for aneuploidy.
    Caldwell S; Almasri E; Schmidt L; Xu C; Dyr B; Wardrop J; Cacheris P
    Prenat Diagn; 2021 Oct; 41(11):1372-1379. PubMed ID: 33682142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-trimester risk assessment based on ultrasound and cell-free DNA vs combined screening: a randomized controlled trial.
    Kagan KO; Sroka F; Sonek J; Abele H; Lüthgens K; Schmid M; Wagner P; Brucker S; Wallwiener D; Hoopmann M
    Ultrasound Obstet Gynecol; 2018 Apr; 51(4):437-444. PubMed ID: 28925570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-Free DNA (cfDNA) Fetal Fraction in Early- and Late-Onset Fetal Growth Restriction.
    Morano D; Rossi S; Lapucci C; Pittalis MC; Farina A
    Mol Diagn Ther; 2018 Oct; 22(5):613-619. PubMed ID: 30056492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A unified approach to risk assessment for fetal aneuploidies.
    Wright D; Wright A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):48-54. PubMed ID: 25315809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for trisomies 21, 18 and 13 by cell-free DNA analysis of maternal blood at 10-11 weeks' gestation and the combined test at 11-13 weeks.
    Quezada MS; Gil MM; Francisco C; Oròsz G; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):36-41. PubMed ID: 25251385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.